Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameGenscript Bio
Stock Code01548
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities全球廣受認同的生命科學研究與應用服務及產品供應商,提供涵蓋生命科學研究服務、生命科學研究目錄產品、臨床前藥物研發服務及工業合成生物產品的綜合服務及產品組合。
Listing Date2015-12-30
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省南京市江寧科學園雍熙路28號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitegenscript.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 1.31 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2015-12-22 to 2015-12-22
Global Offering Shares400,000,000 shares
HK Public Offer Shares (Initial)40,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)360,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,600,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share5.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 524,000,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 49.03B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 2,400,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約6.2百萬美元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 50,800,000
Listing Expenses / Funds Raised~9.69%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 USD
Income Statement
Item 2012201320142015-06
Revenue 52,99060,10469,99441,050
Cost of sales -17,547-21,846-25,896-14,192
Gross profit 35,44338,25844,09826,858
Other income and gains, net 1,6031,1821,468737
Selling and distribution expenses -10,339-12,813-15,538-8,357
Administrative expenses -15,018-16,855-21,446-11,325
Operating profit 11,2747,8668,2477,896
Net finance costs -170-337-4110
Profit before tax 11,1047,5297,8367,896
Income tax expense -1,922-1,529-1,661-2,150
Profit for the year 9,1826,0006,1755,746
Profit attributable to owners 9,1826,0006,1755,746
Balance Sheet
Item 2012201320142015-06
Cash and cash equivalents 18,66022,45725,63725,684
Trade and bills receivables 7,9089,01012,15713,940
Inventories 1,2441,4041,7772,136
Total current assets 30,09938,56143,79243,768
Total current liabilities 30,25229,88529,18823,739
Total equity 44,15652,56361,74768,995
Equity attributable to owners 44,15652,53061,71468,995
Cash Flow Statement
Item 2012201320142015-06
Net cash from operating activities 9,19012,02412,2069,274
Net cash from investing activities -7,317-10,914-9,114-1,121
Net cash from financing activities -991,988395-8,178
Net increase in cash 1,7743,0983,487-25
Depreciation of PP&E 3,6094,4944,7032,384
Amortisation of intangible assets 79477685
Purchase of PP&E -9,529-8,418-7,355-3,747
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.32
First Day OpenHK$ 1.44
First Day Change0.76%
First Day Volume45156000.0
First Day Turnover63397600.0
Use of Proceeds
1、約30%或142.6百萬港元,將用于擴充現有生命科學研究與應用服務及產品組合; 2、約30%或142.6百萬港元,將用于擴充產能; 3、約3%或14.3百萬港元,將用于加強信息科技實力; 4、約12%或57.1百萬港元,將用于鞏固銷售及營銷團隊; 5、約15%或71.3百萬港元,將用于可能收購公司的權益或業務,此舉可補充現有業務、將我們的擴充策略與該等收購相融合,及增加收益及溢利; 6、約10%或47.5百萬港元,將用于補充周轉資金及用于一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
海通国际资本有限公司 CE ADQ859
Overall Coordinators (2)
海通国际证券有限公司 CE AAF806 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Joint Bookrunners (2)
海通国际证券有限公司 CE AAF806 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Joint Lead Managers (4)
海通国际证券有限公司 CE AAF806 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 KGI CAPITAL ASIA LIMITED CE ADT039 RHB SECURITIES HONG KONG LIMITED CE ADU220

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 合贸有限公司 108,730,000 HKD — 5.19% — 6 months 2016-06-30

Directors & Management

PositionChinese nameEnglish Name
Chairman章方良—
Company Secretary黃慧玲—
No director data available.

Major Shareholders

Major Shareholders & Holdings緊隨全球發售及資本化發行完成後,GS Corp持有908,502,024股,佔約56.78%;章方良、王魯泉及王燁作為一致行動人士各自持有約56.11%;吳女士持有約13.19%;KPCB China持有約14.58%。
About this page

This page shows Genscript Bio (01548) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect